Welgene Biotech Co.,Ltd.

Taipei Exchange 6661.TWO

Welgene Biotech Co.,Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 1.87

Welgene Biotech Co.,Ltd. Price to Sales Ratio (P/S) is 1.87 on January 14, 2025, a 0.46% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Welgene Biotech Co.,Ltd. 52-week high Price to Sales Ratio (P/S) is 2.94 on July 22, 2024, which is 57.23% above the current Price to Sales Ratio (P/S).
Welgene Biotech Co.,Ltd. 52-week low Price to Sales Ratio (P/S) is 1.74 on April 16, 2024, which is -7.32% below the current Price to Sales Ratio (P/S).
Welgene Biotech Co.,Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 1.97.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Taipei Exchange: 6661.TWO

Welgene Biotech Co.,Ltd.

CEO	Dr. Yi Xing Lin
IPO Date	Oct. 23, 2017
Location	Taiwan
Headquarters	No. 3, Yuanyuan Street
Employees	80
Sector	Health Care
Industries Biotechnology Research & Consulting

Description

Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization. It also provides reagents, consumable supplies, and instruments, as well as software services. The company was founded in 2003 and is based in Taipei City, Taiwan.

Key trends

Past 5 years